VRTX NASDAQ
Vertex Pharmaceuticals Incorporated
1W: +1.2%
1M: -1.3%
3M: +7.8%
YTD: +15.2%
1Y: +23.6%
3Y: +44.0%
5Y: +181.0%
$521.03
+3.54 (+0.68%)
Weekly Expected Move ±4.1%
$480
$502
$524
$546
$567
Credit Risk of going bust: lower than 94% of companies Debt: 1.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.52 (down 99.9%), Vertex Pharmaceuticals Incorporated would be worth roughly what it owes.
Total debt $1.98B against a stock market value of $132.06B.
Distance to default 17.12 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $988.8M (short-term plus half of long-term), stock volatility 28.8%; Altman Z'' 8.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.52 (down 99.9%), Vertex Pharmaceuticals Incorporated would be worth roughly what it owes.
Total debt $1.98B against a stock market value of $132.06B.
Distance to default 17.12 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $988.8M (short-term plus half of long-term), stock volatility 28.8%; Altman Z'' 8.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
13 relationships6
As Filer
counterparties named
7
As Counterparty
mentioned by others
3
Rel. Types
2021-04-20
Earliest Filing
2024-10-04
Latest Filing
partner: 4
target: 1
acquirer: 1
Counterparties (Filed by VRTX)
6 relationshipsCompanies named in VRTX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Alpine Immune Sciences, Inc. | — | target | Target company in a cash tender offer and merger agreement with Vertex Pharmaceuticals Incorporated. | 2024-04-11 | View |
| Adams Merger Sub, Inc. | — | acquirer | Wholly owned subsidiary of Vertex Pharmaceuticals Incorporated used to execute the cash tender offer and merger. | 2024-04-11 | View |
| CRISPR Therapeutics AG | CRSP | partner | Joint development and commercialization partner for CTX001 | 2021-04-20 | View |
| CRISPR Therapeutics Limited | CRSP | partner | Joint development and commercialization partner for CTX001 | 2021-04-20 | View |
| CRISPR Therapeutics, Inc. | CRSP | partner | Joint development and commercialization partner for CTX001 | 2021-04-20 | View |
| TRACR Hematology Ltd | — | partner | Joint development and commercialization partner for CTX001 | 2021-04-20 | View |
Mentioned As Counterparty
7 mentionsOther companies that named VRTX in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| EDIT Editas Medicine, Inc. | supplier | Licensor of Cas9 gene-editing technology whose future license fees were purchased by the Company's subsidiary | 2024-10-04 | View |
| CRSP CRISPR Therapeutics AG | partner | Amendment to joint development and commercialization agreement for exa-cel | 2023-12-13 | View |
| TRDA Entrada Therapeutics, Inc. | partner | Amendment to Strategic Collaboration and License Agreement and Sublicense Agreement | 2023-11-01 | View |
| GYRE CATALYST BIOSCIENCES, INC. | partner | Counterparty in prior Asset Purchase Agreement referenced in CVR Agreement | 2022-12-27 | View |
| TRDA Entrada Therapeutics, Inc. | partner | Strategic collaboration and license agreement for ENTR-701 development and commercialization, plus equity investment. | 2022-12-08 | View |
| GYRE CATALYST BIOSCIENCES, INC. | target | Acquired Catalyst Biosciences' complement portfolio and related intellectual property for $60 million in cash. | 2022-05-23 | View |
| CRSP CRISPR Therapeutics AG | partner | Amended joint development and commercialization agreement for CTX001 | 2021-04-20 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-20 | Officer/Director Change | View | |
| 2026-09-01 | Officer/Director Change | View | |
| 2026-08-03 | Earnings Release; Exhibits | View | |
| 2026-07-07 | Material Agreement; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-05-13 | Officer/Director Change; Shareholder Vote | View | |
| 2026-05-04 | Earnings Release; Exhibits | View | |
| 2026-04-29 | Officer/Director Change | View | |
| 2026-03-31 | Other Events | View | |
| 2026-02-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-03 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-04 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-05-19 | Other Events | View | |
| 2025-05-14 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-28 | Other Events | View | |
| 2025-02-10 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2024-12-20 | Regulation FD Disclosure | View | |
| 2024-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-08-16 | Entry into Material Definitive Agreement | Agreement | View |
| 2024-08-01 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR